Dr. Grey AI

Daptomycin (Cubicin)

Peptide

Daptomycin is a cyclic lipopeptide antibiotic for serious gram-positive infections. FDA-approved 2003 (cSSSI) and 2006 (S. aureus bacteremia/endocarditis). First-in-class lipopeptide with rapid bactericidal activity against MRSA/MSSA. Phase 3: cSSSI success 83.4% vs 84.2% comparators (n=902). Bacteremia/endocarditis: 44.2% vs 41.7% standard therapy (noninferior, P met). Significantly less nephrotoxicity than vancomycin+gentamicin (11.0% vs 26.3%, P=0.004). SAFETY CONCERN: CPK elevation/myopathy (2.8%), monitor weekly; eosinophilic pneumonia (rare but serious); avoid with statins.

Quick Answer

What it is

Daptomycin is a cyclic lipopeptide antibiotic for serious gram-positive infections. FDA-approved 2003 (cSSSI) and 2006 (S.

Key findings

  • Grade A: Clinical Cure - Skin Infections (cSSSI) (Skin and Soft Tissue Infections)
  • Grade A: Bacteremia/Endocarditis Cure (Staphylococcal Bacteremia and Endocarditis)
  • Grade A: Nephrotoxicity vs Standard Therapy (Staphylococcal Bacteremia and Endocarditis)

Safety

  • SAFETY CONCERN: CPK elevation/myopathy (2.8%), monitor weekly; eosinophilic pneumonia (rare but serious); avoid with statins.
  • Avoid concurrent statins when possible.
⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Daptomycin (Cubicin)

Quick Facts: Daptomycin (Cubicin)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:12
  • Grade A Findings:4
  • Grade B Findings:2
  • Key Effect:Skin and Soft Tissue Infections
A4
B2
C3
D3
2 conditions · 12 outcomes

Detailed Outcomes

|
A
Clinical Cure - Skin Infections (cSSSI)
Pivotal Phase 3 trials (n=902): Clinical success 83.4% daptomycin vs 84.2% conventional therapy (noninferiority met). 4 mg/kg IV once daily for 7-14 days. Effective against MRSA (microbiologic success similar). Noninferior to vancomycin, penicillinase-resistant penicillins.
none
A
Myopathy/CPK Elevation
SAFETY CONCERN: CPK elevation >5x ULN in 2.8% of patients (vs 1.8% comparators). Myopathy/rhabdomyolysis reported. Weekly CPK monitoring recommended. Discontinue if CPK >1000 U/L with symptoms or >2000 U/L asymptomatic. Avoid concurrent statins when possible.
small↓Worsens
B
Eosinophilic Pneumonia Risk
SAFETY CONCERN: Rare but serious eosinophilic pneumonia reported (onset typically 2-4 weeks). Presents with fever, dyspnea, diffuse infiltrates, eosinophilia. Generally reversible upon discontinuation. Also inactivated by pulmonary surfactant - contraindicated for community-acquired pneumonia.
small↑Worsens
A
Bacteremia/Endocarditis Cure
Fowler NEJM 2006 (n=246): Treatment success at 42 days 44.2% vs 41.7% standard therapy (noninferiority met). 6 mg/kg IV daily. Effective for both MRSA and MSSA right-sided endocarditis. CAMERA2 trial: Adding beta-lactam did not improve outcomes vs daptomycin alone.
none
A
Nephrotoxicity vs Standard Therapy
Fowler NEJM 2006: Clinically significant renal dysfunction 11.0% daptomycin vs 26.3% standard therapy (vancomycin+gentamicin), P=0.004. Significant renal-sparing advantage. Does not require renal dose adjustment until CrCl <30 mL/min.
large↓Improves
B
Safety/Tolerability
6 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
small↑Improves
C
Antimicrobial Activity
15 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
moderate↑Improves
C
Liver Protection
3 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
small↑Improves
C
Kidney Function
3 human trials support this finding. Human clinical trial data available.
small↑Improves
D
Sepsis Outcomes
2 human trials support this finding. Human clinical trial data available.
small↓Improves
D
Lipid Profile
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
D
Pulmonary Function
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves

Research Citations (41)

Daptomycin-induced pulmonary eosinophilia: early identification of antibiotic side effects.
(2025)
PMID: 40473316
Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review.
(2025)
PMID: 39216593
Daptomycin Dosage Optimization in Renal Impairment Using Model-Informed Precision Dosing.
(2024)
PMID: 39264343
Lipidation Engineering in Daptomycin Biosynthesis.
(2024)
PMID: 39465544
Daptomycin-Induced Eosinophilic Pneumonia: A Case Report and Systematic Review.
(2024)
PMID: 37963447
Daptomycin for the treatment of acute bacterial meningitis: A narrative review.
(2023)
PMID: 36870402
Daptomycin as an option for lock therapy: a systematic literature review.
(2023)
PMID: 37622290
Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci
(2022)
PMID: 34920946
Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.
(2022)
PMID: 36227704
Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: A randomized clinical trial
(2020)
PMID: 32044943

Related Peptides

Telavancin (Vibativ)

Peptide

1 shared condition · 7 outcomes

Telavancin is a semi-synthetic lipoglycopeptide antibiotic with dual mechanism of action. FDA-approved September 2009 (cSSSI) and June 2013 (HABP/VABP). ATLAS trials (n=1794): Clinical cure 88.3% vs 87.1% vancomycin (noninferior) for cSSSI. ATTAIN trials: Approved for hospital-acquired pneumonia when alternatives not suitable. Coverage: MRSA, MSSA, Streptococci, E. faecalis. SAFETY CONCERN: Higher mortality in patients with pre-existing renal impairment; use when alternatives not suitable.

Oritavancin (Orbactiv)

Peptide

1 shared condition · 5 outcomes

Oritavancin is a second-generation lipoglycopeptide antibiotic for acute bacterial skin infections. FDA-approved August 2014. Single-dose therapy: 1200 mg IV infusion provides complete treatment. SOLO-1 & SOLO-2 Phase 3 (n=1987): Noninferior to 7-10 day vancomycin course (81.2% vs 80.9% composite endpoint). Superior MRSA lesion reduction (93.1% vs 87.1%, P=0.032). Half-life 245 hours enables once-only dosing. Coverage: MRSA, MSSA, Streptococci, E. faecalis. Vancomycin derivative with enhanced lipophilic properties.

Dalbavancin (Dalvance)

Peptide

1 shared condition · 6 outcomes

Dalbavancin is a second-generation lipoglycopeptide antibiotic for acute bacterial skin infections. FDA-approved May 2014. Once-weekly or single-dose therapy: 1500 mg single dose OR 1000 mg + 500 mg at 1 week. DISCOVER-1 & DISCOVER-2 Phase 3: Noninferior to vancomycin/linezolid 14-day course (79.7% vs 79.8%). Half-life >1 week enables weekly dosing. Coverage: MRSA (MIC <0.125 µg/mL), MSSA, Streptococci. Pediatric approval 2021 (birth and older). First single-dose complete ABSSSI treatment.